These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 8986939)

  • 1. Renal protection in diabetes: an emerging role for calcium antagonists.
    Parving HH; Tarnow L; Rossing P
    J Hypertens Suppl; 1996 Nov; 14(4):S21-5. PubMed ID: 8986939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal protection in diabetes--an emerging role for calcium antagonists.
    Parving HH; Tarnow L; Rossing P
    Cardiology; 1997; 88 Suppl 3():56-62. PubMed ID: 9397296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal protection and antihypertensive drugs: current status.
    Salvetti A; Mattei P; Sudano I
    Drugs; 1999 May; 57(5):665-93. PubMed ID: 10353294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcium antagonists and the diabetic hypertensive patient.
    Parving HH; Rossing P
    Am J Kidney Dis; 1993 Jun; 21(6 Suppl 3):47-52. PubMed ID: 8503435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy.
    Tarnow L; Rossing P; Jensen C; Hansen BV; Parving HH
    Diabetes Care; 2000 Dec; 23(12):1725-30. PubMed ID: 11128341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renoprotective action of angiotensin-converting enzyme inhibition in diabetes mellitus.
    Parving HH
    J Cardiovasc Pharmacol; 1992; 19 Suppl 6():S19-24. PubMed ID: 1382160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points.
    Parving HH; Andersen S; Jacobsen P; Christensen PK; Rossing K; Hovind P; Rossing P; Tarnow L
    Semin Nephrol; 2004 Mar; 24(2):147-57. PubMed ID: 15017527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacologic management of diabetic nephropathy.
    Vivian EM; Rubinstein GB
    Clin Ther; 2002 Nov; 24(11):1741-56; discussion 1719. PubMed ID: 12501871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment.
    Rossing P; Tarnow L; Boelskifte S; Jensen BR; Nielsen FS; Parving HH
    Diabetes; 1997 Mar; 46(3):481-7. PubMed ID: 9032106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of nisoldipine and lisinopril on microvascular dysfunction in hypertensive Type I diabetes patients with nephropathy.
    Sørensen VB; Rossing P; Tarnow L; Parving H; Nørgaard T; Kastrup J
    Clin Sci (Lond); 1998 Dec; 95(6):709-17. PubMed ID: 9831696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in pharmacological management of hypertension in diabetic patients with nephropathy. Effects of antihypertensive drugs on kidney function and insulin sensitivity.
    Baba T; Ishizaki T
    Drugs; 1992 Apr; 43(4):464-89. PubMed ID: 1377114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal protection in hypertensive patients: selection of antihypertensive therapy.
    Wenzel RR
    Drugs; 2005; 65 Suppl 2():29-39. PubMed ID: 16398060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on calcium antagonists and the kidney.
    Tobe S
    Curr Opin Nephrol Hypertens; 2003 May; 12(3):309-15. PubMed ID: 12698071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of beta-blockade and angiotensin converting enzyme inhibition on kidney function in diabetic nephropathy.
    Hommel E
    J Hypertens Suppl; 1989 Sep; 7(7):S49-51. PubMed ID: 2575661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of nisoldipine and lisinopril on left ventricular mass and function in diabetic nephropathy.
    Tarnow L; Sato A; Ali S; Rossing P; Nielsen FS; Parving HH
    Diabetes Care; 1999 Mar; 22(3):491-4. PubMed ID: 10097934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-blind trial of perindopril and nitrendipine in incipient diabetic nephropathy.
    Kopf D; Schmitz H; Beyer J; Frank M; Bockisch A; Lehnert H
    Diabetes Nutr Metab; 2001 Oct; 14(5):245-52. PubMed ID: 11806464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diabetic nephropathy. Its relationship to hypertension and means of pharmacological intervention.
    Baba T; Neugebauer S; Watanabe T
    Drugs; 1997 Aug; 54(2):197-234. PubMed ID: 9257079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural history of early diabetic nephropathy: what are the effects of therapeutic intervention? Melbourne Diabetic Nephropathy Study Group.
    Jerums G; Allen TJ; Gilbert RE; Hammond J; Cooper ME; Campbell DJ; Raffaele J
    J Diabetes Complications; 1995; 9(4):308-14. PubMed ID: 8573754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease.
    Palmer AJ; Annemans L; Roze S; Lamotte M; Lapuerta P; Chen R; Gabriel S; Carita P; Rodby RA; de Zeeuw D; Parving HH
    Diabetes Care; 2004 Aug; 27(8):1897-903. PubMed ID: 15277414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.